Senior/Research Associate
NewLimit
Senior/Research Associate
NewLimit
Develops epigenetic medicines to extend healthspan
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.
We are seeking a Research Associate to join our mRNA Engineering team. In this role, you will generate the mRNAs that power NewLimit's research programs, executing the workflow from DNA template through in vitro transcription (IVT) and downstream purification. You will produce research grade mRNA materials, keep rigorous records of how each batch was made, and work closely with scientists across our research and Delivery Sciences teams. This is a lab-based role ideal for an early-career scientist who wants to build deep expertise in mRNA process development in a fast-paced research environment. You will receive hands-on training from expert scientists and see the direct impact of your work on our programs.
As a member of our team, you will:
mRNA production
Documentation and lab operations
Collaboration
NewLimit offers generous benefits to ensure our team can focus on our mission:
Salary Range: $75,000 - $100,000*. Compensation for the role will depend on a number of factors, including a candidate’s qualifications, skills, competencies, and experience. NewLimit offers a competitive benefits package, which includes a 401k, healthcare coverage, and 20 days of PTO. Learn more at: https://www.newlimit.com/careers
*This compensation and benefits information is based on Company's good faith estimate as of the date of publication and may be modified in the future.
NewLimit develops medicines that aim to extend healthy years by reprogramming the epigenome of aging cells. It works by identifying aging-related epigenetic changes using single-cell genomics, machine learning, and high-throughput functional assays, then creating interventions to reverse those changes in targeted tissues such as the immune system and liver. Compared with others, NewLimit combines a specific focus on epigenetic reprogramming with a data-driven, tissue-targeted pipeline and pursues partnerships with pharma and biotech players to develop its proprietary medicines. Its goal is to deliver a new class of medicines that significantly increases the healthspan for patients with age-related diseases.
Explore more opportunities at NewLimit